GLP-1 Innovation team_NSM 2018

1. What is the Incentive amount you are eligible at 100% sales achievement p.a (Both Sales & Activity)?

200000

250000

700000

None of the above

6. In NN, we follow any applicable laws, regulations and industry codes. We also follow our own business ethics standards and procedures (Novo Nordisk Code of ConducAccording to the Business Ethics Code of Conduct, which of the following statements is correct?

Local law and industry code may be disregarded, if my local legal department approves it

Novo Nordisk standards and procedures may be overruled if more stringent rules apply locally

Either of above

7. An employee invites an HCP as a speaker for a meeting to be held on 20th August 2017. You send the request for contract preparation to the legal department by filling up the contract initiation template. Amount to be paid for the services is INR 50,000. When you will calculate FMV?

At the time of payment

At the time of preparation of the contract

Either of the above

None of the above

8. In a Sponsorship, the following is acceptable:

Payment routed to HCP’s directly need not include any follow up documentation.

While Sponsoring an event, commercial benefit for Novo Nordisk and disclosure of the fact that the event has been sponsored by Novo Nordisk is not required if sponsorship amount is below INR 5,00,000.00.

Follow up on fund utilisation is not required if sponsorship amount is below INR 5,00,000.00.

The commercial benefit to Novo Nordisk, disclosure of the fact that the event has been sponsored by Novo Nordisk, agreement and proper follow-up documentation from the institution.

9. Ryzodeg meeting took place on 1st July 2017. Timings as per agenda was 8:00 to 10:00 PM, with dinner scheduled from 9:30 to 10:00 PM. Due to unavoidable circumstances, meeting started at 8:30 PM. Meeting ended at 10:45 pm. But hotel invoice was generated at 12:00 pm. How will you abide by 75/25 rule for the scientific meeting?

I will inform Manager and pay the hotel as per his instructions

I will pay the hotel and thereafter raise exception for deviation from 25/75 rule and document the reason for delay in the start of the meeting

There is no deviation as such in the situation as it occurred due to unavoidable circumstances

None of the above

10. An employee invites a doctor (HCP) as a speaker for a meeting. The HCP accepts the invitation. He is accompanied to the meeting by his friend, who is also a doctor and practices in the field of endocrinology.

It can be accommodated as the friend is also a doctor.

Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies.

Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies. If the friend still attends the event, you should document it

11. Which of the following factors are considered for career progression from a Product Specialist to a Sr product specialist?

3P Rating

Minimum years of experience

Recommendation form Line manager

All of the above

12. Which of the following options regarding Goal Setting is completely TRUE for 2018 process:

Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 5 goals with minimum 10% weight;

Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 10 goals with minimum 5% weight;

Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 10 goals with minimum 5% weight;

Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 12 goals with minimum 5% weight;

13. Which of the following statements is FALSE for 2018 performance management process:

Your performance rating will impact your annual salary increase

Your performance rating will not impact your selection to development programmes

Your 3P rating will serve as an input for career progression

Your performance rating will be solely decided by your manager’s discretion.

15. Which of the following statements is true for 2018 Talent Development Program Nomination

Your performance rating will be considered for your nomination

Your performance rating along with manager’ inputs will be considered for your nomination

Your cumulative health score card will be considered for your nomination

Your sales performance will be considered for your nomination

16. All employees should report any customer complaint (Product defect/AE/SAE) or safety information to

Safety Team (INAGREE@novonordisk.com)

GM (General Manager)

HQ (Head Quarters)

None of the above

19. In case if you observe errors in label, promotional material contact

Line Manager & QA

No need to report to any one

Distribute to HCP with error

Do not know

20. Corrections to printed or handwritten data must be made so that the original text is:

Strikethrough so nothing is readable

Strikethrough but readable

Completely covered using a whitener

Enter duplicate data

21. Which are the key components of MACE?

Cardiovascular death & Non-fatal Myocardial Infarction

Cardiovascular death, Non-fatal Myocardial Infarction & Heart Failure

Cardiovascular death, Non-fatal Myocardial Infarction & Non- Fatal Stroke

Hospitalisation for acute coronary syndrome, Urgent revascularisation procedures & Heart failure

22. What is expanded 4-point MACE?

Hospitalisation for acute coronary syndrome, Urgent revascularisation procedures & Heart failure

Cardiovascular death, Non-fatal Myocardial Infarction & Heart Failure & fatal Myocardial Infarction

Cardiovascular death, Non-fatal Myocardial Infarction, Non- Fatal Stroke & hospitalisation for unstable angina or heart failure

Cardiovascular death, Non-fatal Stroke, Heart Failure & fatal Myocardial Infarction

25. If the Hazard ratio of CV outcome study comparing Drug A with Placebo is 1.87. It means:

Drug A has more CV risk

Placebo has less CV risk

Drug A has less CV risk

Both Drug A & Placebo increase the CV risk

27. In LEADER trial the hazard ratio for CV death in liraglutide arm :

Decreased By 22% But Was Non-Significant

Increased By 26% But Was Non-Significant

Decreased By 22% But Was Significant

Increased By 15% But Was Significant

29. Effects of GLP-1 on the cardiovascular system are:

Improves cardiac function in heart failure

Increases myocardial glucose uptake

Mproves functional recovery following myocardial ischaemia

Reduces infarct size & improves endothelium dysfunction

All of the above

30. The reduction in CV events with liraglutide appeared independent of:

Baseline insulin or CV medication use

Initiation of insulin or SU/TZD during the trial

Experiencing an episode of severe hypoglycemia

All of the above

31. Regarding Dulaglutide and liraglutide which one is false:

The molecular size of Dulaglutide is 59 kD and liraglutide is 3.9 kD

The needle gauge in dulaglutide pen in 29 G and liraglutide is 31 G

Dulaglutide achieved non inferiority over liraglutide on weight parameters in AWARD 6

Both dulaglutide and liraglutide are human based GLP-1 analogues

37. The percentage of patients achieving HbA1c target of <7 m% with liraglutide and dulaglutide is AWARD -6 is :

70.2 and 68.4

67.9 and 68.3

65.7 and 69.2

72.2 and 71.3

38. Which of the following is true regarding the design of AWARD -6 :

4 week lead in period followed by 26 weeks treatment period and 4 week safety follow up

2 week lead in period followed by 26 weeks treatment period and 4 week safety followup

2 week lead in period followed by 56 weeks treatment period and 4 week safety followup

D) 4 week lead in period followed by 56 weeks treatment period and 2 week safety followup

39. Select the most probable reason for less weight loss with dulaglutide in comparison to liraglutide in AWARD -6 in spite :

Larger size of the molecule makes dulaglutide less available in the blood circulation

Larger size of dulaglutide makes entry into the CNS difficult

Lower effect on the gastric emptying with dulaglutide

More nausea with liraglutide causes more weight loss

40. Select the wrong option from the below ones regarding AWARD -6 in spite :

PRIMARY OBJECTIVE : Non-inferiority of dulaglutide 1.5 mg to liraglutide 1.8 mg on

KEY SECONDARY OBJECTIVE : Superiority of dulaglutide 1.5 mg to liraglutide 1.8 mg on HbA1c change from baseline to Week 26

One of the Key exclusion criteria was Elevated calcitonin (≥20 pg/ml)

One of the Key inclusion criteria was HbA1c ≥8.0% and ≤11.0%

42. Primary Endpoint of LEADER trial was the occurrence of:

Death from any cause or Death from MI or death from stroke

Death from MI or non-fatal MI or non-fatal stroke

Death from cardiovascular causes or non-fatal MI or non-fatal stroke

Any death from any cause

43. In LEADER trial patients were randomized to

Liraglutide : Glargine

Liraglutide : Placebo

Liraglutide : Exenatide

Liraglutide : Semaglutide

45. LEADER trial included ……………. Patients who were at high risk for cardiovascular disease

Type 1 diabetes

Type 2 diabetes

Both

None

50. According to Kapitza et al , the reduction with liraglutide and lixisenatide in weight (%) in 28 days is :

3.4 and 1.6

1.6 and 2.4

2.4 and 1.6

1.6 and 3.4

Unlock and Upgrade

Remove all limits from your Quizzes

GLP-1 Innovation team_NSM 2018

More Quizzes